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Abstract
Background: The prognostic value of the status of O6-methylguanine-DNA methyltransferase (MGMT)
promoter methylation measured by pyrosequencing assay (PSQ) among glioblastoma (GBM) patients was
examined in meta-analysis.
Methods: Eligible studies that reported the association between the status of MGMT promoter methylation
by PSQ and prognostic value of GBM patients from three electronic databases, like PubMed, EMBASE, and
Cochrane library were involved in meta-analysis. Using Stata 11.0, the summarized hazard ratios (HRs) for
overall survival (OS) and the progression-free survival (PFS) with 95 % confidence interval (CI) were calculated.
Results: Eleven studies were included to evaluate the relationship between the status of MGMT promoter methylation
and GBM patients’ survival. Overall, regardless of the cut-off value of methylation status of MGMT promoter by PSQ,
methylated-positive patients were evidently associated with an improved HRs for OS (HRs = 0.50, 95 % CI = 0.35–0.66).
For summary, progression-free survival (PFS) from four studies, the prognostic effect was also found (HRs = 0.56, 95 %
CI = 0.32–0.80).
Conclusion: Methylation positivity of MGMT promoter by PSQ was related to an increased survival in GBM patients.
Thus, the status of MGMT promoter methylation by PSQ might be used to be a prognostic biomarker, and GBM
patients might have a vested interest in clinical application of standardized PSQ.
Keywords: MGMT, Meta-analysis, Glioblastoma, Hazard ratio, Pyrosequencing, Survival, Prognostic biomarker
Background
Glioblastoma (GBM), accounting for approximately
16 % of primary brain and central nervous system tu-
mors in adults [1], has a poor prognosis with the median
survival no more than 12 months [2], despite advances
in chemotherapy, radiotherapy, surgery, and multi-
modal treatments. A number of studies document that
some molecular markers, such as IDH1/IDH2 [3], 1p/
19q co-deletion [4], and MGMT promoter methylation
[5], have become an integral part of tumor assessment in
modern oncology practice. In 2016, the new World
Health Organization (WHO) Classification of Tumors of
the Central Nervous System (2016 CNS WHO) was
launched to replace the 2007 CNS WHO. The new clas-
sification system integrates phenotypic and genotypic
diagnoses, for example, GBM, on the basis of histo-
logical diagnosis, which is grouped into GBM IDH-
wildtype, GBM IDH-mutant, and GBM NOS (not other-
wise specified) with IDH mutational status; thus, pa-
tients will benefit from greater diagnostic accuracy as
well as improved patient management and more accur-
ate determinations of prognosis and treatment response
[6]. Although classification has been established on the
basis of IDH status among GBM, some studies indicated
that IDH mutation, MGMT promoter methylation
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status, 1p/19q loss independently associated with favor-
able outcome in temozolomide (TMZ) + radiotherapy-
treated GBM patients. Meanwhile, it was found that
MGMT promoter methylation is a predictive marker for
benefit from alkylating agents only in high-grade glioma
patients with IDH1 wildtype, but 1p/19q loss in high-
grade glioma patients with IDH1 mutant [7]. Nevertheless,
in this meta-analysis, the predictive or prognostic role of
MGMT promoter methylation among GBM was assessed.
MGMT, a DNA repair protein, removes the alkylation
of the O6 position of guanine which is the most cyto-
toxic lesion induced by alkylating agent chemotherapy,
such as nitrosoureas or temozolomide (TMZ) [8, 9].
Low-level expression of MGMT protein causes impaired
ability to repair DNA. Hyper-methylation of MGMT
gene promoter might result in silencing gene expression
and further down-regulate protein concentrations [10].
Since a landmark study by Hegi [11] 11 years ago, nu-
merous studies have confirmed that methylation status
of MGMT promoter can serve as a predictive factor for
the outcome of GBM patients aged less than 60 years,
following alkylating agent chemotherapy [12, 13], or a
prognostic factor in non-elderly GBM patients [14].
Compared with other assays, like immunohistochemistry
with poor inter-observer reliability and time-consuming
procedure, direct testing status of MGMT promoter
methylation might be convenient for clinical application.
Varying quantitative and qualitative assays, such as MSP,
methylation-sensitive high-resolution melting and PSQ,
and bisulfite sequencing [15] have been used to examine
the methylation status of CpGs island that mainly regu-
lates MGMT protein expression at the epigenetic level,
in MGMT promoter. Among these techniques, PSQ is a
sequence-by-synthesis method that is the only method
respectively analyzing methylation levels of each CpGs
and providing quantitative information on the percent-
age of CpGs methylation [16].
Thus, to our knowledge, this is the first meta-analysis
that has evaluated the role of MGMT promoter methyla-
tion in predicting the prognosis of GBM patients. In this
meta-analysis, because of the prognostic value of methyla-
tion status of MGMT promoter by PSQ for survival of
GBM patients unclear and no in consensus, we summa-
rized relevant data to quantify the prognostic value of
methylation status of MGMT promoter by PSQ, using
standard meta-analysis techniques, regardless of impact
factors, such as age of patients, therapy modality, etc.
Methods
We carried out review and meta-analysis following the
Cochrane Handbook of systematic reviews and re-
ported results on the basis of Preferred Reporting Item
for Systematic Reviews and Meta-Analysis (PRISMA)
statement.
Literature screening
For obtaining a maximum of interested studies, we re-
trieved literatures in MEDLINE, EMBASE, and Cochrane
library (as of Jan. 2016) using the following searching strat-
egy: “(glioblastoma OR glioma) AND (MGMT OR O6-
methylguanine-DNA methyltransferase) AND methyla-
tion”. It was performed with English restriction and limited
to human studies.
Study selection
The publications were firstly screened by title and ab-
stract by two reviewers, and substantially full-text of po-
tentially eligible studies was reviewed for potential
studies under definitive inclusion criteria. Inclusion cri-
teria: (1) studies published the correlation between
methylation status of MGMT promoter by PSQ and
patients’ outcome; and (2) available data of HR and 95 %
CI or p value for OS as primary outcome or PFS among
GBM patients were extracted, irrespectively of the
threshold of methylation status of MGMT promoter the
amount of CpGs islands measured by PSQ, disease stage,
treatment strategy (whether or not treated with alkylat-
ing agent chemotherapy), sample source, etc. Any dis-
agreement or discrepancies were resolved by discussion
between less than three reviews.
Data extraction
From eligible publications, general profiles, like the name
of the first author, publication year, country, age of
patients, the number of patients, cut-off value of methyla-
tion status of MGMT promoter by PSQ, sample source,
and treatment experience, as well as disease status,
were extracted through two independent reviewers.
HRs that were correlated with methylation status of
MGMT promoter by PSQ and survival of GBM patients
(OS or PFS as outcome) were extracted in multivariate
analysis and pooled.
Assessment of methodological quality
In the context of the Newcastle-Ottawa scale (NOS),
which consists of eight items that are categorized into
three groups (selection, comparability, and outcome/
exposure), two reviewers were involved to assess the
methodological quality of eligible studies. Studies with
scores of 1–3, 4–6, and 7–9 were considered as low,
intermediate, and high quality, respectively.
Data analysis
For correlation between the status of MGMT promoter
methylation by PSQ and patients’ survival, HRs were
computed and pooled from each included studies in two
cohorts. The fixed-effects or random-effects models
were chosen depending on heterogeneity between in-
cluded studies (assessed by the I2 statistic test). The I2
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values of 0 to 40 %, 30 to 60 %, 50 to 90 %, and 75 to
90 % indicate no important, moderate, substantial, and
considerable heterogeneity, respectively [17]. For signifi-
cant heterogeneity of studies, we attempted to identify
the sources of variation between studies by analyzing the
subgroup results and excluding them. Finally, random-
effects model was used to pool the results. Because of
the amount limitation of eligible studies, sensitivity and
publication bias was not undertaken. In this meta-
analysis, p value was transformed into 95 % CI through
formulas [18].
In the two-tailed test, the results were considered to be
statistically significant with a p value of <0.05. The meta-
analysis was performed with Stata 11.0 (Stata Corporation,
College Station, Austin, TX).
All analyses were based on the previous published
studies; thus, no ethical approval and patient consent
were required.
Results
Study selection and ascertainment
Using our searching strategy, 2819 publications were found
from three database, PubMed-MEDLINE, EMBASE, and
Cochrane library. Following reviewing titles and abstracts,
2601 publications were excluded and 218 candidates were
included for further assessment. Among these 218 poten-
tial publication candidates, ten eligible publications which
reported results of 11 studies, all being observational study,
were chosen and could successfully extract data for meta-
analysis, after excluding review, letter care report, no
interesting reports in publication. Flowchart of identifica-
tion for eligible studies was shown in Fig. 1.
Basic characteristic and quality assessment of eligible
studies
The main characteristic of the eligible studies was
shown in Table 1. All the included 11 prospective
cohort studies investigated the association between
methylation status of MGMT promoter by PSQ and
GBM patients’ survival and reported HR for OS. Of
these, four studies presented HR for PFS [19–22]. The
age of GBM patients enrolled in the 11 studies ranged
widely. In five studies [19, 22–25], 10 % was referred as
the cut-off value of the presence of MGMT promoter
methylation, 9 % in four studies [26–28], and 8 % in
two studies [20, 21]. The amount of CpGs tested by
PSQ did not reach an agreement in eligible studies, but
at least five CpGs were measured. Of the 11 included
studies, not all GBM patients were treated with alkylat-
ing agent in three studies [23–25, 28].
In the context of Newcastle-Ottawa quality assess-
ment scale (NOS), the mythological quality of eligible
publications was evaluated by two reviewers. The
methodological quality of the included 11 studies was
evaluated to be intermediate with the score range of
5–6 points, and no study obtained full marks. In cat-
egory selection, four items, such as representativeness
of the exposed cohort, selection of the non-exposed
cohort, ascertainment of exposure, and demonstration
that outcome of interest, were fully depicted in the 11
Fig. 1 The flowchart of publication search and selection of eligible studies
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Table 1 The profiles of eligible studies
Publication
year





CpGs Sample source No. patientsa Disease status Treatment experience Score in
NOS
2015 Dae Cheol Kim Korea 51.4 (26.4–87.2) 9 % 5 CpGs FFPE 104 Newly diagnosed
GMB
No all patients treated with TMZ 5
2015 Robert W. Rapkinsb Australia 58.3 (25.0–85.0) 9 % 5 CpGs FFPE 303 Newly diagnosed
GMB
Surgery + radiotherapy + TMZ+
adjuvant TMZ
6
2015 Robert W. Rapkinsb Australia 57.8 (22.3–84.3) 9 % 5 CpGs FFPE 303 Newly diagnosed
GMB
Surgery + radiotherapy + TMZ+
adjuvant TMZ
5
2014 Veronique Quillien France 58 (21.0–73.0) 9 % 16 CpGs FFPE 89 Newly diagnosed
GMB
Stupp protocol 5
2014 Vincent Peter Collins UK 53 (41–60) 10 % 16 CpGs FFPE 275 Recurrent high-
grade GMB
PCV OR two TMZ schedules 5
2014 Dong Shen China 56 (35–71) 10 % 12 CpGs FFPE 128 Recurrent high-
grade GMB
Surgery + radiotherapy + TMZ+
adjuvant TMZ
5
2012 Guido Reifenberge Germany 74.1 (70.0–86.6) 8 % 5 CpGs Frozen sample 85 Newly diagnosed
GMB
Treated with alkylating agents 5




Standard care treatment 5





2011 Shani Mulholland Sweden NA 10 % 16 CpGs Frozen sample 362 GMB Surgery + adjuvant treatment (no TMZ) 5




Surgery + radiotherapy + TMZ+
adjuvant TMZ
5
Abbreviations: FFPE formalin-fixed paraffin-embedded, PCV chemotherapy procotol: procarbazine, CCNU, and vincristine
aThe number of patients whose methylation status of MGMT promoter was measured successfully by PSQ













studies. In comparability, no control of confounding
factors was reported in the 11 eligible studies with all
studies scoring 0 point. Only one study depicted that
researchers were independently blinded to assess
MGMT status by PQS and patients outcomes, and
finally, follow-up duration and losses of subjects were
not described in all studies (shown in Table 1).
Overall survival
HR and 95 % CI could be extracted or calculated
from p value. In this meta-analysis, HRs for OS were
analyzed and summarized from three subgroups in
which 8, 9, or 10 % as cut-off value was carried out
to consider the presence of MGMT promoter methy-
lation in the 11 studies.
In general, MGMT promoter methylation was associ-
ated with an HRs for improved OS of 0.50 (95 % CI
0.35–0.66) with statistical heterogeneity (I = 84.5 %, p =
0.000, random-effects model). The results of subgroup
analysis showed that subgroup classification could not
reduce heterogeneous level with the value of I no less
than 85 % (Fig. 2).
After rejecting the data from four studies in which no all
patients undergoing alkylating agent chemotherapy, gen-
eral HRs was 0.42 (95 % CI 0.31–0.53) with statistical
heterogeneity (I = 67.8 %, p = 0.005). In addition, in sub-
group 9 %, no obvious heterogeneity was evidenced (p <
0.05), and heterogeneity was still in existence in subgroup
10 and 8 % (Fig. 3).
Progression-free survival
For HRs of PFS, data from four studies were used in
meta-analysis, and no subgroups were classified because
of limited amounts of eligible studies. Following pooling
results in random-effects model, the GBM patients
with methylated MGMT promoter had a significantly
longer PFS (HR = 0.56, 95 % CI = 0.32–0.80) compared
with un-methylated MGMT promoter with statistic
heterogeneity (I = 80.6 %, p = 0.001) (shown in Fig. 4).
Discussion
According to profiling studies of GBM by The Cancer
Genome Atlas (TCGA) project, varying subtypes with
unique biological behaviors, were identified, such as
proneural, neural, classical, and mesenchymal [29] or
proneural, proliferative, and mesenchymal [30]. In the
context of subtypes by TCGA, Brennan CW et al.
found that MGMT promoter status distinguished
responders from non-responders to TMZ among sam-
ples classified as classical but not among samples
classified as proneural, mesenchymal, and neural, evi-
dencing that MGMT promoter methylation might
only have such predictive validity in classical subtype
GBM [31]. The high rate of MGMT promoter hyper-
methylation was found long-term GBM survivors that
would be of the proneural subtype [32]. In addition,
despite methylated-positive MGMT promoter has
been recognized with predictive value for ≤60-year-old
GBM patients treated with TMZ [12, 13] and prognos-
tic value in non-elderly GBM patients [14], the results
Fig. 2 Forest plots of the association of methylation status of MGMT promoter by PSQ with OS among GBM patients
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are controversial between different studies. The rea-
sons for inconsistency in the results might be that
statistical limitation (e.g., small sample size), differ-
ence ethnicity of involved subjects, or methodological
diversity (e.g., the amount of CpGs detected by PSQ
or cut-off value for methylated positivity or tumor
sample source). Therefore, the meta-analysis of com-
bining the results from different studies can present
direct and definite evidences. Meanwhile, expanding
sample-size in the context of homogeneity among
including studies in meta-analysis might increase
statistical power.
In current meta-analysis, subgroup analysis based on
varied cut-off value of MGMT promoter methylation
was preformed to address abovementioned issues, and
further provide up-to-date clinical evidence for applying
MGMT promoter methylation by PSQ as a prognostic
biomarker for GBM patients. The result of this meta-
analysis showed that, compared with patients with non-
methylated MGMT promoter, methylated-positive patients
had longer OS and PFS. However, statistical heterogeneity
among studies that reported HRs of OS or PFS was
observed. Because of adopted varied cut-off value ranged
from 8 to 10 % for methylation positivity of MGMT
Fig. 4 HRs for PFS with methylated-positive versus un-methylated cohorts
Fig. 3 Forest plots of the association of methylation status of MGMT promoter by PSQ with OS among GBM patients after deleting data from
four studies in which no all patients treated with alkylating agent
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promoter in included studies, three subgroups with cut-off
value 10, 9, and 8 % were divided, and then subgroup
analysis was undertook according to cut-off value in order
to identify the association between the cut-off value and
heterogeneity, but the significant heterogeneity was still
found. In addition, following simply rejecting data from
four studies in which no all GBM patients treated with
alkylating agent or from two studies enrolling recurrent
GBMs patients, obvious heterogeneity was still in exist-
ence. Therefore, the cut-off value of MGMT promoter
positivity with PSQ and therapy modality might not be the
main reason for high level of heterogeneity in this meta-
analysis. Other factors, such as sample size, age, and
follow-up duration were investigated, but no heteroge-
neous sources were identified.
Methylation of CpGs sites in MGMT promoter, one of
the major post-transcriptional mechanisms reducing
MGMT protein expression, has been found in 40 % of
cancer such as glioma and colorectal cancer and in 25 %
of non-small cell lung carcinoma, lymphoma, and head
and neck carcinoma [33, 34]. Furthermore, the extent of
methylation has an impact on the expression levels of
MGMT protein [35]. Thus, it is mechanistically reason-
able that the methylation status of MGMT promoter
might be regarded as a prognostic biomarker for GBM
patients treated with alkylating agent. In comparison
with other assay, PSQ yields quantitative results, and
high intra- and inter-laboratory reproducibility for a
commercially available MGMT PSQ kit is documented
in a ring trial [36]. However, standard operation proced-
ure of PSQ should be established, and accuracy should
be determined soon.
There were some limitations in this meta-analysis.
Firstly, the number of eligible studies included was lim-
ited, and outcome measures recorded differently in the
studies. Especially, only four studies were involved for
PFS, so the results should be interpreted with cautions.
Secondly, statistical heterogeneity among these studies
that reported HR for OS and PFS were observed, and the
source of heterogeneity were not able to be determined
simply by subgroup analysis on the basis of the cut-off
value of MGMT promoter methylation by PSQ or reject-
ing data from four studies in which no all patients under-
went alkylating agent chemotherapy. Thirdly, due to
limited number of studies included in this meta-analysis,
sensitivity analysis and publication bias were not been
evaluated. Fourthly, the cohort studies included in this
meta-analysis had an intermediate methodological quality
with no more than 6 points in NOS, so there were some
methodological issues. Lastly, although Karnofsky per-
formance score, age, sex, etc. were analyzed as potential
prognostic factors in multivariate analysis in the 11 eligible
studies, no studies in this meta-analysis explained the
control of confounding factors.
Conclusions
In spite of above limitations, our meta-analysis indicated
that the methylation status of MGMT promoter were
related to the improved prognosis by PSQ and should be
considered as a strong prognostic biomarker among GBM
patients post-TMZ therapy. According to methylation
status by PSQ, stratification medication might be applied
among GBM patients in coming clinical practice.
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